| Talquetamab, a T-cell–redirecting GPRC5D bispecific antibody for multiple myeloma A Chari, MC Minnema, JG Berdeja, A Oriol, NWCJ van de Donk, ... New England Journal of Medicine 387 (24), 2232-2244, 2022 | 228 | 2022 |
| Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial M Dimopoulos, RG Sanz, HP Lee, M Trneny, M Varettoni, S Opat, S D'Sa, ... Blood advances 4 (23), 6009-6018, 2020 | 70 | 2020 |
| Updated phase 1 results from MonumenTAL-1: first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients … AY Krishnan, MC Minnema, JG Berdeja, A Oriol, NWCJ van de Donk, ... Blood 138, 158, 2021 | 61 | 2021 |
| Diffuse alveolar damage and thrombotic microangiopathy are the main histopathological findings in lung tissue biopsy samples of COVID-19 patients FS Beigee, MP Toutkaboni, N Khalili, SA Nadji, A Dorudinia, M Rezaei, ... Pathology-Research and Practice 216 (10), 153228, 2020 | 53 | 2020 |
| Talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): phase 1/2 results … A Chari, C Touzeau, C Schinke, MC Minnema, J Berdeja, A Oriol, ... Blood 140 (Supplement 1), 384-387, 2022 | 45 | 2022 |
| Prevalence, risk factors and outcomes associated with acute kidney injury in patients hospitalized for COVID‐19: a comparative study between diabetic and nondiabetic patients S Khalili, T Sabaghian, M Sedaghat, Z Soroureddin, E Askari, N Khalili Journal of diabetes research 2021 (1), 6666086, 2021 | 34 | 2021 |
| Prevalence of transthyretin amyloidosis in patients with heart failure and no left ventricular hypertrophy A Devesa, A Camblor Blasco, AM Pello Lazaro, E Askari, G Lapeña, ... ESC Heart Failure 8 (4), 2856-2865, 2021 | 33 | 2021 |
| Updated results of a phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D)× CD3 bispecific antibody, in relapsed … JG Berdeja, AY Krishnan, A Oriol, NWCJ van de Donk, P Rodríguez-Otero, ... Journal of Clinical Oncology 39 (15_suppl), 8008-8008, 2021 | 32 | 2021 |
| Case report: COVID-19-associated rhinosinusitis mucormycosis caused by Rhizopus arrhizus: a rare but potentially fatal infection occurring after treatment with corticosteroids P Tabarsi, N Khalili, M Pourabdollah, S Sharifynia, AS Naeini, J Ghorbani, ... The American journal of tropical medicine and hygiene 105 (2), 449, 2021 | 28 | 2021 |
| Phase 1b results for subcutaneous talquetamab plus daratumumab in patients with relapsed/refractory multiple myeloma A Chari, P Hari, NJ Bahlis, MV Mateos, NWCJ van de Donk, B Dholaria, ... Blood 138, 161, 2021 | 23 | 2021 |
| Development and validation of a predictive model of in-hospital mortality in COVID-19 patients D Velasco-Rodríguez, JM Alonso-Dominguez, R Vidal Laso, ... PloS one 16 (3), e0247676, 2021 | 22 | 2021 |
| NETosis in ischemic/reperfusion injuries: An organ-based review P Hashemi, M Nouri-Vaskeh, L Alizadeh, A Baghbanzadeh, ... Life Sciences 290, 120158, 2022 | 20 | 2022 |
| Xanthohumol: An underestimated, while potent and promising chemotherapeutic agent in cancer treatment S Vesaghhamedani, F Ebrahimzadeh, E Najafi, OG Shabgah, E Askari, ... Progress in biophysics and molecular biology 172, 3-14, 2022 | 18 | 2022 |
| Subcutaneous teclistamab in combination with daratumumab for the treatment of patients with relapsed/refractory multiple myeloma: results from a phase 1b multicohort study P Rodriguez-Otero, B Dholaria, E Askari, DE Reece, NWCJ van de Donk, ... Blood 138, 1647, 2021 | 17 | 2021 |
| Emerging infectious endocarditis due to Scedosporium prolificans: a model of therapeutic complexity ML Fernandez Guerrero, E Askari, E Prieto, I Gadea, A Román European journal of clinical microbiology & infectious diseases 30, 1321-1324, 2011 | 16 | 2011 |
| S183: Novel combination immunotherapy for the treatment of relapsed/refractory multiple myeloma: Updated phase 1B results for talquetamab (A GPRC5D x CD3 bispecific antibody … NW Van de Donk, N Bahlis, MV Mateos, K Weisel, B Dholaria, AL Garfall, ... HemaSphere 6, 84-85, 2022 | 14 | 2022 |
| COVID-19 associated rhinosinusitis mucormycosis due to Rhizopus oryzae: A rare but potentially fatal infection occurring after treatment with corticosteroids P Tabarsi, N Khalili, M Pourabdollah, S Sharifynia, AS Naeini, J Ghorbani, ... | 11 | 2021 |
| Waldenström’s macroglobulinemia: An exploration into the pathology and diagnosis of a complex B-cell malignancy E Askari, S Rodriguez, R Garcia-Sanz Journal of Blood Medicine, 795-807, 2021 | 10 | 2021 |
| Comparative evaluation of SARS-CoV-2 IgG assays against nucleocapsid and spike antigens M Rezaei, M Sadeghi, A Korourian, P Tabarsi, M Porabdollah, E Askari, ... Human Antibodies 29 (2), 109-113, 2021 | 10 | 2021 |
| Preparation of a novel zinc zirconate nanocomposite coated on glass for removal of a textile dye (Reactive Brilliant Red X8B) from water MH Habibi, E Askari Synthesis and Reactivity in Inorganic, Metal-Organic, and Nano-Metal …, 2015 | 10 | 2015 |
